摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-甲基-4-溴-3-甲基苯磺酰胺 | 923148-87-2

中文名称
N-甲基-4-溴-3-甲基苯磺酰胺
中文别名
N-甲基4-溴-3-甲基苯磺酰胺
英文名称
4-bromo-N,3-dimethylbenzenesulfonamide
英文别名
4-bromo-3-methyl-N-methyl-benzenesulfonamide
N-甲基-4-溴-3-甲基苯磺酰胺化学式
CAS
923148-87-2
化学式
C8H10BrNO2S
mdl
MFCD08868519
分子量
264.143
InChiKey
VKXILHHKRMMVQB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    54.6
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2935009090

SDS

SDS:6600d04c26b0e3f5f1b36f63308e8040
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: N-Methyl 4-bromo-3-methylbenzenesulfonamide
Synonyms: 4-Bromo-N,3-dimethylbenzenesulfonamide

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: N-Methyl 4-bromo-3-methylbenzenesulfonamide
CAS number: 923148-87-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10BrNO2S
Molecular weight: 264.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-甲基-4-溴-3-甲基苯磺酰胺1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物potassium acetate联硼酸频那醇酯 作用下, 以 1,4-二氧六环 为溶剂, 以18%的产率得到2-甲基-4-(N-甲基磺酰基)苯硼酸
    参考文献:
    名称:
    New bicyclic compounds as crac channel modulators
    摘要:
    这项发明涉及一种新型化合物,它们是CRAC通道活性的抑制剂。该发明还涉及含有这些化合物的药物组合物,它们的制备方法以及它们在治疗中的应用。
    公开号:
    EP2738172A1
  • 作为产物:
    描述:
    4-溴-3-甲基苯磺酰氯甲胺乙酸乙酯盐酸Sodium sulfate-III 作用下, 以 四氢呋喃 为溶剂, 反应 3.0h, 以to provide 4-bromo-3-methyl-N-methyl-benzenesulfonamide (4.2 g, 85.7%) as a white solid的产率得到N-甲基-4-溴-3-甲基苯磺酰胺
    参考文献:
    名称:
    Naphthylacetic acids
    摘要:
    本发明涉及式I的化合物及其药学上可接受的盐和酯,其中X、Q和R1-R6在详细说明和权利要求中有定义。此外,本发明还涉及制造和使用式I化合物的方法,以及含有这些化合物的药物组合物。式I化合物是CRTH2受体的拮抗剂或部分激动剂,可用于治疗与该受体相关的疾病和障碍,如哮喘。
    公开号:
    US08124629B2
点击查看最新优质反应信息

文献信息

  • [EN] NAPHTHYLACETIC ACIDS<br/>[FR] ACIDES NAPHTYLACÉTIQUES
    申请人:HOFFMANN LA ROCHE
    公开号:WO2010055005A1
    公开(公告)日:2010-05-20
    The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
    本发明涉及式(I)的化合物以及药用可接受的盐和酯,其中X、Q和R1-R6在详细描述和权利要求中定义。此外,本发明还涉及制造和使用式(I)化合物的方法,以及包含此类化合物的药物组合物。式(I)的化合物是CRTH2受体的拮抗剂或部分激动剂,可用于治疗与该受体相关的疾病和失调,如哮喘。
  • INDOLE DERIVATIVES AS CRAC MODULATORS
    申请人:Alam Muzaffar
    公开号:US20110071150A1
    公开(公告)日:2011-03-24
    Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 and R 4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).
    公式I的化合物: 或其药用可接受的盐, 其中R1、R2、R3和R4按本文定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与释放激活通道(CRAC)相关疾病的用途。
  • [EN] ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS<br/>[FR] PYRROLES CONDENSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE CRAC
    申请人:GRUENENTHAL GMBH
    公开号:WO2015022073A1
    公开(公告)日:2015-02-19
    The invention relates to substituted bicyclic pyrroloheterocyclyl compounds of general formula (I), wherein A1 and A2 represent direct bond or C(=O), with the proviso that 0 or 1 of A1 and A2 represents C(=O); m and n independently denote 0, 1, 2 or 3, with the proviso that the sum [n + m] is 1, 2, 3 or 4; R1 denotes H, F, CI, Br, I, CN, CF3, CF2H, CFH2, CO2H, CO2R13, R13, OH. O-R13, NH2, N(H)R13, N(R13)2, R2 represents 0 to 4 substituents, each independently selected from F, CI, Br, CN. CF3, CF2H, CFH2, R13, OH, O-R13, NH2, N(H)R13 and N(R13)2; Ar1 represents phenyl or 5- or 6-membered heteroaryl, in each case unsubstituted or substituted with one, two, three or four substituents, independently selected from F, CI, Br, CN, CF3. CF2H, CFH2, R13 and O- R13; or C3-6-cycloalkyl or 3 to 7 membered heterocycloalkyl, in each case unsubstituted or mono- or polysubstituted; Ar2 represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or said heteroaryl may be unsubstituted or mono- or polysubstituted and may be condensed with a 4-, 5-, 6-or 7- membered ring, being carbocyclic or heterocyclic, wherein said condensed ring may be saturated, partially unsaturated or aromatic and may be unsubstituted or mono- or polysubstituted; useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.
    该发明涉及通式(I)的取代双环吡咯杂环基化合物,其中A1和A2代表直接键或C(=O),但A1和A2中的0或1个代表C(=O);m和n独立地表示0、1、2或3,但要求总和[n + m]为1、2、3或4;R1代表H、F、CI、Br、I、CN、CF3CF2H、CFH2、CO2H、CO2R13、R13、OH、O-R13、NH2、N(H)R13、N(R13)2;R2表示0到4个取代基,每个独立地选自F、CI、Br、CN、 、CF2H、CFH2、R13、OH、O-R13、NH2、N(H)R13和N(R13)2;Ar1表示苯基或5-或6-成员杂芳基,每种情况下未取代或取代为一个、两个、三个或四个取代基,独立地选自F、CI、Br、CN、 、CF2H、CFH2、R13和O-R13;或C3-6-环烷基或3到7-成员杂环烷基,每种情况下未取代或单取代或多取代;Ar2表示苯基或5-或6-成员杂芳基,其中所述苯基或所述杂芳基可以未取代或单取代或多取代,并且可以与4-、5-、6-或7-成员环融合,为碳环或杂环,所述融合环可以饱和、部分不饱和或芳香,并且可以未取代或单取代或多取代;用作ICRAC抑制剂,用于含有这些化合物的药物组合物,以及用于治疗和/或预防疾病和/或疾病,特别是炎症性疾病和/或炎症性疾病的这些化合物。
  • MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS
    申请人:HADIDA RUAH SARA S.
    公开号:US20090143381A1
    公开(公告)日:2009-06-04
    Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    本发明的化合物及其药用可接受的组合物可用作ATP结合盒(“ABC”)转运蛋白或其片段的调节剂,包括囊性纤维化跨膜传导调节蛋白(“CFTR”)。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
  • ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS
    申请人:Frackenpohl Jens
    公开号:US20110230350A1
    公开(公告)日:2011-09-22
    Use of substituted sulfonamides of the formula (I) or salts thereof for enhancing stress tolerance in plants to abiotic stress, especially for enhancing plant growth and/or for increasing plant yield.
    使用式(I)的替代磺胺或其盐来增强植物对非生物胁迫的耐受性,特别是用于增强植物生长和/或增加植物产量。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫